CLOS
PACB icon

Compagnie Lombard Odier SCmA’s Pacific Biosciences PACB Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,000
Closed -$1K – 921
2016
Q2 		$1K Buy
+2,000
New +$18.3K ﹤0.01% 892

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Compagnie Lombard Odier SCmA's PACB Position: Q3 2021 in Review

Compagnie Lombard Odier SCmA sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 12,500 shares — an estimated $370K sold.

Compagnie Lombard Odier SCmA first reported a position in PACB in Q1 2014 and held it in 24 quarters. The position peaked at $1.21M in Q3 2016. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 12,500 Pacific Biosciences shares in Q3 2021, an estimated $370K.
  • Compagnie Lombard Odier SCmA first reported a position in Pacific Biosciences in Q1 2014 and held it in 24 quarters.
  • Compagnie Lombard Odier SCmA's Pacific Biosciences position peaked at $1.21M in Q3 2016.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2021, filed 28 Oct 2021.